Use of long-acting progesterone to acyclic embryo recipient mares

The objective of this study was to evaluate the efficiency of cyclic and acyclic progesterone-treated recipient mares in a commercial embryo transfer program. Acyclic recipients were treated with decreasing amounts of estradiol cypionate (ECP® - Pfizer Saúde Animal, São Paulo, Brazil), followed by 1500 mg of a sustained-release progesterone injection (P4LA150® - Laboratórios B.E.T., Rio de Janeiro, Brazil). Out of all 1506 embryo recovery attempts performed, 59.36% were positive (894/1506). Pregnancy rates of cyclic and acyclic mares were, respectively, 44.12% (319/723) and 57.68% (139/241) - higher in acyclic recipients under progesterone treatment. Embryo loss was similar between groups (9.72% 31/319 vs. 11.51% - 16/139). When fertility data on acyclic mares treated with long-action progesterone were grouped in relation to the interval of the beginning of the treatment with progesterone to the embryo transfer, there was no difference in pregnancy rates at 12 days (51.28% - 20/39; 58.92% - 33/56; 60.52% - 46/76 and 58.57% - 41/70 for embryos transferred 3 (P3), 4 (P4), 5 (P5) and 6 (P6) days after the beginning of the treatment with progesterone). Groups P3, P4, P5 and P6 showed embryo loss rates of 20.00% (4/20), 12.12% (4/33), 2.17% (1/46) and 17.07% (7/41), respectively. These rates were similar in groups P3, P4 and P6. Pregnant recipients submitted to an embryo transferring procedure on P5 showed lower embryo mortality rates than on P3 and P6. P4 recipients tended to suffer higher embryo mortality rates than P5. Acyclic recipient mares under progesterone treatment can be satisfactoryly used in embryo transfer programs.

Saved in:
Bibliographic Details
Main Authors: Greco,Gabriel Maksoud, Burlamaqui,Fábio Luis Gonçalves, Pinna,Aline Emerim, Queiroz,Fernando José Rohen de, Cunha,Maria Pia dos Santos, Brandão,Felipe Zandonadi
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Zootecnia 2012
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-35982012000300019
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-35982012000300019
record_format ojs
spelling oai:scielo:S1516-359820120003000192012-04-25Use of long-acting progesterone to acyclic embryo recipient maresGreco,Gabriel MaksoudBurlamaqui,Fábio Luis GonçalvesPinna,Aline EmerimQueiroz,Fernando José Rohen deCunha,Maria Pia dos SantosBrandão,Felipe Zandonadi embryo loss embryo transfer mare pregnancy The objective of this study was to evaluate the efficiency of cyclic and acyclic progesterone-treated recipient mares in a commercial embryo transfer program. Acyclic recipients were treated with decreasing amounts of estradiol cypionate (ECP® - Pfizer Saúde Animal, São Paulo, Brazil), followed by 1500 mg of a sustained-release progesterone injection (P4LA150® - Laboratórios B.E.T., Rio de Janeiro, Brazil). Out of all 1506 embryo recovery attempts performed, 59.36% were positive (894/1506). Pregnancy rates of cyclic and acyclic mares were, respectively, 44.12% (319/723) and 57.68% (139/241) - higher in acyclic recipients under progesterone treatment. Embryo loss was similar between groups (9.72% 31/319 vs. 11.51% - 16/139). When fertility data on acyclic mares treated with long-action progesterone were grouped in relation to the interval of the beginning of the treatment with progesterone to the embryo transfer, there was no difference in pregnancy rates at 12 days (51.28% - 20/39; 58.92% - 33/56; 60.52% - 46/76 and 58.57% - 41/70 for embryos transferred 3 (P3), 4 (P4), 5 (P5) and 6 (P6) days after the beginning of the treatment with progesterone). Groups P3, P4, P5 and P6 showed embryo loss rates of 20.00% (4/20), 12.12% (4/33), 2.17% (1/46) and 17.07% (7/41), respectively. These rates were similar in groups P3, P4 and P6. Pregnant recipients submitted to an embryo transferring procedure on P5 showed lower embryo mortality rates than on P3 and P6. P4 recipients tended to suffer higher embryo mortality rates than P5. Acyclic recipient mares under progesterone treatment can be satisfactoryly used in embryo transfer programs.info:eu-repo/semantics/openAccessSociedade Brasileira de ZootecniaRevista Brasileira de Zootecnia v.41 n.3 20122012-03-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-35982012000300019en10.1590/S1516-35982012000300019
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Greco,Gabriel Maksoud
Burlamaqui,Fábio Luis Gonçalves
Pinna,Aline Emerim
Queiroz,Fernando José Rohen de
Cunha,Maria Pia dos Santos
Brandão,Felipe Zandonadi
spellingShingle Greco,Gabriel Maksoud
Burlamaqui,Fábio Luis Gonçalves
Pinna,Aline Emerim
Queiroz,Fernando José Rohen de
Cunha,Maria Pia dos Santos
Brandão,Felipe Zandonadi
Use of long-acting progesterone to acyclic embryo recipient mares
author_facet Greco,Gabriel Maksoud
Burlamaqui,Fábio Luis Gonçalves
Pinna,Aline Emerim
Queiroz,Fernando José Rohen de
Cunha,Maria Pia dos Santos
Brandão,Felipe Zandonadi
author_sort Greco,Gabriel Maksoud
title Use of long-acting progesterone to acyclic embryo recipient mares
title_short Use of long-acting progesterone to acyclic embryo recipient mares
title_full Use of long-acting progesterone to acyclic embryo recipient mares
title_fullStr Use of long-acting progesterone to acyclic embryo recipient mares
title_full_unstemmed Use of long-acting progesterone to acyclic embryo recipient mares
title_sort use of long-acting progesterone to acyclic embryo recipient mares
description The objective of this study was to evaluate the efficiency of cyclic and acyclic progesterone-treated recipient mares in a commercial embryo transfer program. Acyclic recipients were treated with decreasing amounts of estradiol cypionate (ECP® - Pfizer Saúde Animal, São Paulo, Brazil), followed by 1500 mg of a sustained-release progesterone injection (P4LA150® - Laboratórios B.E.T., Rio de Janeiro, Brazil). Out of all 1506 embryo recovery attempts performed, 59.36% were positive (894/1506). Pregnancy rates of cyclic and acyclic mares were, respectively, 44.12% (319/723) and 57.68% (139/241) - higher in acyclic recipients under progesterone treatment. Embryo loss was similar between groups (9.72% 31/319 vs. 11.51% - 16/139). When fertility data on acyclic mares treated with long-action progesterone were grouped in relation to the interval of the beginning of the treatment with progesterone to the embryo transfer, there was no difference in pregnancy rates at 12 days (51.28% - 20/39; 58.92% - 33/56; 60.52% - 46/76 and 58.57% - 41/70 for embryos transferred 3 (P3), 4 (P4), 5 (P5) and 6 (P6) days after the beginning of the treatment with progesterone). Groups P3, P4, P5 and P6 showed embryo loss rates of 20.00% (4/20), 12.12% (4/33), 2.17% (1/46) and 17.07% (7/41), respectively. These rates were similar in groups P3, P4 and P6. Pregnant recipients submitted to an embryo transferring procedure on P5 showed lower embryo mortality rates than on P3 and P6. P4 recipients tended to suffer higher embryo mortality rates than P5. Acyclic recipient mares under progesterone treatment can be satisfactoryly used in embryo transfer programs.
publisher Sociedade Brasileira de Zootecnia
publishDate 2012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-35982012000300019
work_keys_str_mv AT grecogabrielmaksoud useoflongactingprogesteronetoacyclicembryorecipientmares
AT burlamaquifabioluisgoncalves useoflongactingprogesteronetoacyclicembryorecipientmares
AT pinnaalineemerim useoflongactingprogesteronetoacyclicembryorecipientmares
AT queirozfernandojoserohende useoflongactingprogesteronetoacyclicembryorecipientmares
AT cunhamariapiadossantos useoflongactingprogesteronetoacyclicembryorecipientmares
AT brandaofelipezandonadi useoflongactingprogesteronetoacyclicembryorecipientmares
_version_ 1756422331015626752